U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07220135) titled 'Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer' on Oct. 13.
Brief Summary: This is a randomized phase II study to evaluate the pathological complete response (pCR) rate with two neoadjuvant regimens (Docetaxel+Carboplatin+Herceptin/Perjeta and Docetaxel+Herceptin/Perjeta) in HER2 amplified/positive early breast cancer.
Study Start Date: Nov. 14
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: Carboplatin
All of the treatment being received by the study participants during the course of the study is standard of care.
DRUG: Docetaxel
All of the treatment being received by the...